Humanized Mouse as a Tool to Predict Immunotoxicity of Human Biologics

Kylie Su Mei Yong,Zhisheng Her,Sue Yee Tan,Wilson Wei Sheng Tan,Min Liu,Fritz Lai,Shi Min Heng,Yong Fan,Kenneth Tou En Chang,Cheng-I Wang,Jerry Kok Yen Chan,Jianzhu Chen,Qingfeng Chen
DOI: https://doi.org/10.3389/fimmu.2020.553362
IF: 7.3
2020-10-15
Frontiers in Immunology
Abstract:Advancements in science enable researchers to constantly innovate and create novel biologics. However, the use of non-human animal models during the development of biologics impedes identification of precise <i>in vivo</i> interactions between the human immune system and treatments. Due to lack of this understanding, adverse effects are frequently observed in healthy volunteers and patients exposed to potential biologics during clinical trials. In this study, we evaluated and compared the effects of known immunotoxic biologics, Proleukin<sup>®</sup>/IL-2 and OKT3 in humanized mice (reconstituted with human fetal cells) to published clinical outcomes. We demonstrated that humanized mice were able to recapitulate <i>in vivo</i> pathological changes and human-specific immune responses, such as elevated cytokine levels and modulated lymphocytes and myeloid subsets. Given the high similarities of immunological side effects observed between humanized mice and clinical studies, this model could be used to assess immunotoxicity of biologics at a pre-clinical stage, without placing research participants and/or patients at risk.
immunology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the effectiveness of humanized mice as a tool for predicting the immunotoxicity of human biological products. Specifically, the researchers hope to verify whether humanized mice can accurately simulate the response of the human immune system by comparing the effects of biological products known to have immunotoxicity (such as Proleukin®/IL - 2 and OKT3) in humanized mice with the results of clinical trials, so as to evaluate the immunotoxicity of biological products in the pre - clinical stage and avoid risks to healthy volunteers or patients. ### Main research questions: 1. **Can humanized mice accurately simulate the response of the human immune system to biological products?** - The researchers constructed a humanized mouse model by transplanting human fetal cells into mice and tested the response of these mice to biological products known to have immunotoxicity (such as Proleukin®/IL - 2 and OKT3). 2. **Can humanized mice reproduce the immunotoxic side effects observed in clinical trials?** - By comparing the immune responses observed in humanized mice and clinical trials, the researchers hope to verify the effectiveness of the humanized mouse model in predicting the immunotoxicity of biological products. ### Research background: - **Challenges in the development of biological products**: In the research and development process of biological products, it is difficult to accurately predict the response of the human immune system using non - human animal models, resulting in frequent adverse reactions in clinical trials. - **Advantages of humanized mice**: By transplanting human immune cells, humanized mice can more accurately simulate the response of the human immune system, thereby evaluating the safety of biological products in the pre - clinical stage. ### Research methods: - **Experimental design**: The researchers used a humanized mouse model and administered Proleukin®/IL - 2 and OKT3 respectively, and observed and recorded the immune responses of the mice. - **Data analysis**: The immune responses of the mice were evaluated by methods such as flow cytometry, cytokine detection, and histological analysis, and compared with clinical trial data. ### Research results: - **Immune response to Proleukin®/IL - 2**: - After treatment with Proleukin®/IL - 2, humanized mice showed an inflammatory response similar to that of clinical patients, including pulmonary edema, cytokine storm (such as increased IFN - γ, IL - 12p70, IL - 17A, IL - 18, IL - 23, IL - 33 and IL - 10), and significant expansion of multiple immune cell subsets. - **Immune response to OKT3**: - After treatment with OKT3, humanized mice also showed an immune response similar to that of clinical patients, including cytokine storm (such as increased IFN - γ and TNF - α) and T - cell activation. ### Conclusion: - The humanized mouse model can accurately simulate the response of the human immune system to biological products, especially having high accuracy in predicting immunotoxic side effects. Therefore, humanized mice can be used as an effective tool to evaluate the immunotoxicity of biological products in the pre - clinical stage and reduce the potential risks to healthy volunteers and patients.